5835-79-0

Basic information

• Product Name: 4-MORPHOLIN-4-YL-BUTAN-1-OL
• Synonyms: 4-Morpholinobutan-1-ol;AKOS BB/0085;4-MORPHOLIN-4-YL-BUTAN-1-OL;CHEMBRDG-BB 4001148;AKOS BBB/436;4-morpholin-4-ylbutan-1-ol(SALTDATA: FREE)
• CAS NO: 5835-79-0
• Molecular Formula: C₈H₁₇NO₂
• Molecular Weight: 159.22608
• Mol File: 5835-79-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 255.368°C at 760 mmHg
• Flash Point: 108.243°C
• Appearance: /
• Density: 1.016g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.47
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-MORPHOLIN-4-YL-BUTAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-MORPHOLIN-4-YL-BUTAN-1-OL(5835-79-0)
• EPA Substance Registry System: 4-MORPHOLIN-4-YL-BUTAN-1-OL(5835-79-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 5835-79-0(Hazardous Substances Data)

Usage

General Description

4-MORPHOLIN-4-YL-BUTAN-1-OL is a chemical compound with the molecular formula C8H17NO2. It is an organic compound with a morpholine ring and a butanol side chain. 4-MORPHOLIN-4-YL-BUTAN-1-OL is commonly used as a reagent or building block in the synthesis of various pharmaceuticals and other organic compounds. It serves as a versatile intermediate in the production of drugs and other bioactive molecules. 4-MORPHOLIN-4-YL-BUTAN-1-OL is an important chemical in the field of organic chemistry and is used in various research and industrial applications.

InChI:InChI=1/C8H17NO2/c10-6-2-1-3-9-4-7-11-8-5-9/h10H,1-8H2

Upstream product

• 88217-57-6 3-morpholin-4-ylpropionic acid ethyl ester 
• 5807-11-4 3-(morpholin-4-yl)-butanenitrile 
• 929257-58-9 3-morpholinopropyl 2-(3-(trifluoromethyl)phenylamino)pyridine-3-carboxylate 
• 110-91-8 morpholine 
• 110-63-4 Butane-1,4-diol 
• 5471-53-4 methyl 4-morpholinobutanoate 
• 4753-59-7 4-Bromobutyl acetate 
• 928-51-8 4-Chloro-1-butanol 

Downstream Products

• 32066-00-5 3,4,5-trimethoxy-benzoic acid 4-morpholin-4-yl-butyl ester 
• 102466-21-7 3,4,5-trimethoxy-trans-cinnamic acid-(4-morpholino-butyl ester) 
• 98997-74-1 4-(4-chlorobutyl)morpholine hydrochloride 
• 5807-07-8 4-morpholin-4-yl-butyraldehyde 
• 929257-58-9 3-morpholinopropyl 2-(3-(trifluoromethyl)phenylamino)pyridine-3-carboxylate 

Relevant articles and documents

DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.

Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation

Novel morpholinyl (4a) and piperazinylalkyl (4b-e) esters were synthesized and evaluated in vitro for their properties as bioreversible topically administered dermal prodrugs of naproxen. These ionizable prodrugs exhibited various aqueous solubilities and lipophilicities, depending on the pH of medium. As indicated by octanol-buffer partition coefficients (logP(app)) at pH 7.4, all of the prodrugs were significantly more lipophilic (logP(app)=0.7-3.9) than naproxen (logP(app)=0.3). Furthermore, the most aqueous of the soluble prodrugs (4b-d) were only 2-3-fold less soluble in an aqueous buffer of pH 7.4 (~30-50 mM) than was naproxen (~100 mM). At a pH of 5.0, prodrugs showed a generally higher aqueous solubility and similar logP(app) values, compared to naproxen. The chemical and enzymatic hydrolysis of prodrugs at 37°C was investigated in aqueous buffer solutions (pH 5.0 and 7.4) and in 80% human serum (pH 7.4), respectively. The prodrugs showed moderate chemical stability (t(1/2)=15-150 days at pH 5.0), and they were hydrolyzed enzymatically to naproxen, with half-lives ranging from 0.4 to 77 min. In permeation studies using post-mortem human skin in vitro, the flux of naproxen was 6.5 and 1.6 nmol/cm2.h in a saturated aqueous buffer vehicle of pH 7.4 and 5.0, respectively. Among the prodrugs, two piperazinyl derivatives (4c and 4d) resulted in a 9- and 4-fold enhancement of permeation, respectively, when compared to naproxen itself at pH 7.4. 4c also resulted in a significantly (4-fold) better permeation than naproxen at pH 5.0. In conclusion, piperazinyl esters improved skin permeation of naproxen and are promising prodrugs of naproxen for topical drug delivery. Copyright (C) 2000 Elsevier Science B.V.

Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs

Quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs (NSAIDs) are disclosed. These esters and thioesters display the anti--inflammatory profile of the parent NSAIDs with greatly reduced gastrointestinal irritancy, providing a more favorable separation of therapeutic activity and toxicological side effects than the parent NSAIDs.